aTyr Pharma, Inc.
ATYR
$3.28
$0.185.81%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.40% | -52.20% | -32.16% | -29.62% | -96.25% |
| Total Depreciation and Amortization | -100.25% | -60.93% | -34.64% | 1.99% | -41.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 194.74% | 144.76% | 96.68% | -133.67% | -139.72% |
| Change in Net Operating Assets | -53.96% | 223.84% | -26,476.47% | -172.95% | 185.43% |
| Cash from Operations | -18.71% | -37.65% | -70.27% | -3,693.22% | -6.68% |
| Capital Expenditure | -47.06% | 97.31% | 99.67% | 98.64% | 98.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -134.02% | 263.58% | 479.28% | 96.37% | 472.00% |
| Cash from Investing | -134.15% | 309.45% | 261.89% | 96.45% | 791.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -11.30% | -15.74% | -17.14% | -83.33% | -74.24% |
| Issuance of Common Stock | 208.46% | -99.28% | 66.48% | -84.16% | 540.52% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 212.21% | -103.91% | 67.12% | -84.38% | 557.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -102.96% | 287.77% | 96.06% | -249.11% | 271.63% |